Please login to the form below

Not currently logged in
Email:
Password:

Adcetris

This page shows the latest Adcetris news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    did not achieve a complete response, with Adcetris reducing that measure by 23% compared to the control group. ... Crucially, Adcetris avoids the use of the chemotherapy drug bleomycin, which can be associated with severe and unpredictable toxicity.

  • Takeda bags EU approval for Adcetris in lymphoma Takeda bags EU approval for Adcetris in lymphoma

    months on Adcetris, as well as improvements in median progression-free survival (PFS) and overall response rate, and symptom burden. ... The approval of Adcetris in this setting brings a much needed, effective treatment option to patients living with CTCL

  • Seattle Genetics' Adcetris earns FDA priority review status Seattle Genetics' Adcetris earns FDA priority review status

    Seattle Genetics’ Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the lymphoma drug priority review status. ... Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the

  • NICE reverses stance on Takeda’s Adcetris NICE reverses stance on Takeda’s Adcetris

    Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin) after persuading NICE to change its mind and issue new draft guidance. ... But much to the Japanese firm’s dismay NICE’s final appraisal

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    Keytruda is cleared for use in adults who have failed a stem cell transplant and have already tried or are ineligible for Takeda's Adcetris (brentuximab vedotin).

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

  • Pharma deals during April 2013 Pharma deals during April 2013

    This passion has seemingly been ignited further by the recent FDA approvals of Kadcyla (Genentech/ ImmunoGen) and Adcetris (Seattle Genetics) both following impressive clinic trials in HER2 breast cancer and lymphoma,

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics